Corcept Therapeutics
CORT Nasdaq· Pharmaceuticals
Last close · Oct 27, 2026
$87.59
KIRA · Stoqly’s AI analyst, in plain words
- Corcept Therapeutics had $761M of revenue in fiscal 2025, up 12.8% on the year before. Over five years, revenue changed +16.6% a year on average.
- Its operating margin was 5.9%, down 14.4 pts: of every 100 in sales, about 6 is left after running the business.
- Corcept Therapeutics made $99.7M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 31.4% a year.
- Free cash flow was $142M in fiscal 2025, 18.6% of revenue.
- Corcept Therapeutics returned $173M to shareholders in fiscal 2025, 122% of free cash flow. The diluted share count rose 5.7%.
- Corcept Therapeutics has $372M more cash than debt.
Market cap
$10.4B
P/E
—
Revenue
$761M
Net income
$99.7M
Free cash flow
$142M
Operating margin
5.9%
Corcept Therapeutics in 30 seconds · fiscal 2025
Are sales growing?
+12.8%
Yes. Sales grew 12.8% last year.
Does it make a profit?
13.1%
Yes. It keeps 13.1% of every sale as profit.
Does profit turn into cash?
18.6%
Yes. 18.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
What Corcept Therapeutics does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- CORCEPT THERAPEUTICS INC
- CIK
- 0001088856
Corcept Therapeutics · CORT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $366M | $402M | $482M | $675M | $761M |
| Revenue growth | 3.4% | 9.8% | 20.0% | 39.9% | 12.8% |
| Gross margin | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% |
| Operating margin | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Net income | $113M | $101M | $106M | $141M | $99.7M |
| Net margin | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
| Diluted EPS | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Cash | |||||
| Cash from operations | $168M | $120M | $127M | $198M | $142M |
| Capital expenditure | $0.5M | $0.4M | $0.1M | $2.2M | $0.2M |
| Free cash flow | $167M | $120M | $127M | $196M | $142M |
| FCF margin | 45.8% | 29.8% | 26.2% | 29.1% | 18.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $15.7M | $173M |
| Share count change | 1.4% | −7.9% | −3.6% | 1.6% | 5.7% |
| Debt and strength | |||||
| Cash and short-term investments | $224M | $432M | $368M | $383M | $372M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $376M | $502M | $507M | $680M | $648M |
| Net debt / EBITDA | −1.8x | −3.8x | −3.4x | −2.8x | −8.1x |
| Current ratio | 5.6x | 6.9x | 4.4x | 3.4x | 2.9x |
| Returns and quality | |||||
| Return on capital | 95.4% | 88.4% | 87.6% | 55.1% | 15.7% |
| Return on equity | 25.0% | 23.1% | 21.1% | 23.8% | 15.0% |
| Piotroski F-score | 4 | 8 | 4 | 5 | 3 |
| Altman Z'' | 15.1 | 14.2 | 11.6 | 10.2 | 9.0 |
Insiders bought, 12 months
$3.3M
1 insider
Insiders sold, 12 months
$101M
10 insiders
Of sales under plans
93%
$94.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Corcept Therapeutics · CORT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics CORT | $10.4B | 12.8% | 5.9% | 18.6% | 15.7% | — | 3 |
| Collegium Pharmaceutical COLL | $748M | 23.6% | 23.0% | 42.0% | 53.4% | 18.5x | 6 |
| Amphstar Pharmaceuticals AMPH | $1.1B | −1.7% | 19.5% | 16.8% | 9.9% | 15.1x | 6 |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.4x | 6 |
| Acadia Pharmaceuticals ACAD | $3.5B | 11.9% | 9.8% | 9.8% | — | 9.0x | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $87.59 a share, the company is worth $10.4B.
Corcept Therapeutics grew sales faster than 2 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001088856). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.